Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
Classifica tra le azioni
#3772
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
Prezzo delle azioni
$4.87
Capitalizzazione di mercato
$4.36B
Variazione (1 giorno)
-5.47%
Variazione (1 anno)
-15.62%
Paese
CN
Scambia Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Categoria
Healthcare
Ricavi di Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Ricavi nel Oct 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd da 2006 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2025 | $600.18M | 267.03% |
| 2024 | $163.52M | 14.15% |
| 2023 | $143.25M | 19.70% |
| 2022 | $119.67M | -18.11% |
| 2021 | $146.13M | 45.75% |
| 2020 | $100.27M | -40.70% |
| 2019 | $169.09M | 1.82% |
| 2018 | $166.06M | -2.09% |
| 2017 | $169.60M | 22.48% |
| 2016 | $138.47M | 2.49% |
| 2015 | $135.11M | 7.86% |
| 2014 | $125.26M | 4.39% |
| 2013 | $119.99M | 25.65% |
| 2012 | $95.50M | 26.69% |
| 2011 | $75.38M | 45.08% |
| 2010 | $51.96M | 44.63% |
| 2009 | $35.92M | 53.80% |
| 2008 | $23.36M | 84.39% |
| 2007 | $12.67M | 186.16% |
| 2006 | $4.43M | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $10.11B | - |
BE
|
|
| $6.02B | - |
NL
|
